|1.||Kataoka, Hiroaki: 18 articles (07/2015 - 06/2003)|
|2.||Lin, Chen-Yong: 12 articles (01/2014 - 01/2002)|
|3.||Fukushima, Tsuyoshi: 9 articles (01/2014 - 09/2005)|
|4.||Kataoka, H: 7 articles (02/2007 - 02/2000)|
|5.||Hamasuna, R: 6 articles (02/2007 - 02/2000)|
|6.||Itoh, H: 6 articles (02/2007 - 02/2000)|
|7.||Koono, M: 6 articles (11/2001 - 02/2000)|
|8.||Johnson, Michael D: 5 articles (01/2014 - 05/2003)|
|9.||Dickson, Robert B: 5 articles (07/2006 - 01/2002)|
|10.||Itoh, Hiroshi: 5 articles (02/2006 - 06/2003)|
|1.||Breast Neoplasms (Breast Cancer)
01/15/2007 - "To examine the in vitro regulation of hepatocyte growth factor activator inhibitor type 2 (HAI-2) in breast cancer cells and the in vivo predictive role for the efficacy of chemoendocrine primary therapy in patients with breast cancer. "
01/15/2007 - "Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer."
01/01/2002 - "Matriptase and its cognate inhibitor, HGF activator inhibitor 1 (HAI-1) colocalize on the cell periphery of breast cancer cells and form stable complexes in the extracellular milieu, suggesting that the inhibitor serves to prevent undesired proteolysis in these cells. "
03/01/2003 - "Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer."
06/19/2015 - "Novel Role for γ-Catenin in the Regulation of Cancer Cell Migration via the Induction of Hepatocyte Growth Factor Activator Inhibitor Type 1 (HAI-1)."
12/01/2014 - "Hepatocyte growth factor activator inhibitor type‑1 in cancer: advances and perspectives (Review)."
08/01/2009 - "The role of hepatocyte growth factor activator inhibitor-1 (HAI-1) as a prognostic indicator in cervical cancer."
01/01/2009 - "We investigated the role of hepatocyte growth factor activator inhibitor-2 (HAI-2) and evaluated its clinical importance in cervical cancer. "
01/01/2009 - "Hepatocyte growth factor activator inhibitor-2 (HAI-2) is a favorable prognosis marker and inhibits cell growth through the apoptotic pathway in cervical cancer."
|3.||Neoplasm Metastasis (Metastasis)
09/18/2014 - "In this study, we delineated the role of hepatocyte growth factor activator inhibitor-2 (HAI-2) in prostate cancer (PCa) cell migration, invasion, tumorigenicity and metastasis using a human PCa progression model (103E, N1, and N2 cells) and xenograft models. "
07/01/2015 - "On the other hand, the expression of human kallikrein 1-related peptidase (KLK) 4, which activates plasma HGF activator zymogen, in prostate cancer patients with bone metastasis or advanced stage has also been reported. "
10/21/2005 - "To provide the expression profile of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 (HAI-1) in normal and malignant tissues of gastrointestinal tract at mRNA level for further study on their correlations with tumor progression and metastasis. "
02/01/2011 - "Hepatocyte growth factor activator inhibitor type 1 suppresses metastatic pulmonary colonization of pancreatic carcinoma cells."
01/01/2014 - "Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is a membrane-bound serine protease inhibitor that is expressed on the surface of epithelial and carcinoma cells. "
01/01/2014 - "Exposing eight human carcinoma cells to pH 6.0 buffer induced robust matriptase zymogen activation followed by rapid inhibition of the nascent active matriptase by hepatocyte growth factor activator inhibitor (HAI)-1. "
07/01/2006 - "Matriptase and its cognate inhibitor, hepatocyte growth factor activator inhibitor-1 (HAI-1), have been implicated in carcinoma onset and malignant progression. "
01/15/2012 - "Although hepatocyte growth factor activator inhibitor-1 (HAI-1) represents the predominant endogenous inhibitor for matriptase and the protein molar ratio of HAI-1 to matriptase is determined to be >10 in epithelial cells and the majority of carcinoma cells, an inverse HAI-1-to-matriptase ratio is seen in some ovarian and hematopoietic cancer cells. "
|5.||Prostatic Neoplasms (Prostate Cancer)
01/01/2014 - "Expression of hepatocyte growth factor activator inhibitor-1 (HAI-1) gene in prostate cancer: clinical and biological significance."
02/01/2013 - "Expression of Hepatocyte growth factor activator inhibitor type-1 (HAI-1) in prostate cancer."
10/01/2007 - "Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro."
04/01/2006 - "Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer."
10/01/2005 - "Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer."
|1.||Serine Proteases (Serine Protease)
|3.||Messenger RNA (mRNA)
|4.||Conditioned Culture Media
|5.||pro-hepatocyte growth factor
|6.||Complementary DNA (cDNA)
|9.||RNA-Directed DNA Polymerase (Reverse Transcriptase)
|10.||Hepatocyte Growth Factor (Growth Factor, Hepatocyte)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Transplantation (Transplant Recipients)